智通财经APP讯，药明生物(02269)发布2026年中期业绩，该集团取得收益117.87亿元，同比增长18.4%;毛利54.48亿元，同比增长28.1%;公司拥有人应占纯利24.4亿元，同比增长4.3%;公司拥有人应占经调整纯利33.06亿元，同比增长38.4%;每股基本盈利0.6元。
公告称，收益增长反映了本集团在各项目阶段及各区域市场的全面增长，主要归因于新 IND赋能项目的强劲需求、多个项目持续推进至后期临床开发及商业化生产，以及北美市场的稳健增长。
于报告期内，本集团的一体化端到端CRDMO平台及“跟随并赢得分子”战略持续推动项目组合实现稳健增长。截至2026年6月30日，本集团共新增169个综合项目，使得综合项目总数达1064个，其中临床后期及商业化生产项目数分别增长至78个及28个。本集团亦于报告期内通过“赢得分子”战略获得16个外部项目，包括四个临床后期项目及一个商业化生产项目，为未来增长提供进一步动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.